Prognostic Value of CD64 Marker for Patients in Intensive Care Unit

Systemic Inflammatory Response Syndrome Clinical Trial

— CD64  

Official title:

Prognostic Value of CD64 Marker for Patients in Intensive Care Unit

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03617796
• Other study ID #: PSS2017/CD64-GIBOT/MS
• Status: Not yet recruiting
• Start date: September 10, 2018
• Est. completion date: December 31, 2018

Study information

• Verified date: July 2018
• Source: Central Hospital, Nancy, France
• Contact: Sebastien GIBOT, professor
• Phone: 0383852970
• Email: s.gibot[@]chru-nancy.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Among patients admitted to the intensive care unit (ICU), early recognition of those with the highest risk of death is of paramount importance. Since clinical judgment is sometimes uncertain biomarkers could provide additional information likely to guide critical illness management. We want to evaluate the prognostic value of leucocyte surface expression of CD64.

Blood samples for CD64 biomarker measurement will be obtained daily during the patient's hospitalization. The primary outcome was all-cause death at D28 after admission

Description:

Some local or systemic biological markers, using highly specialized techniques, have an interest that remains quite marginal in routine.

Markers of inflammation generally have elevated concentrations in circulating blood, but these increases are not specific for prognosis. This is the case of pro-inflammatory cytokines (TNF, IL-1, IL-6...)[1, 2] and especially, so-called'acute phase' proteins such as C-reactive protein (CRP) and procalcitonin. It is now well established that the rise in the CRP is totally non-specific. With regard to procalcitonin, the published data are far from univocal[3-4], in particular because of the heterogeneity of the populations studied (emergency services, medical services, intensive care).

These conventional biological assays are therefore not very informative and less efficient than the clinical-biological scores used in routine (SAPSII and SOFA).

An alternative diagnostic approach relies on molecular changes in the cellular compartment of innate immunity. Activation of neutrophil polymorphils (PNN) is the result of the pro/anti-inflammatory cytokinic balance and hormonal cascades In other words, the degree of activation of NNPs can be considered as the barometer of the intensity of any acute inflammatory phenomenon. One of the most specific indicators of a systemic inflammatory response is the increased expression of CD64, a high affinity receptor to the immunoglobulin fragment Fcγ, on the surface of PNNs.

CD64 expression elevation is induced in 4-6 hours by numerous cytokines (G-CSF, IFN- γ[5-7]. Given the very low basal expression level of CD64 (less than 2000 sites per cell) and its rate of elevation in case of inflammation, its determination could prove interesting in demonstrating the inflammatory response and its intensity.

In addition, the measurement of CD64 expression has obvious advantages over other PNN activation markers (such as CD11b, CD18, CD16, CD45RA or CD62L): negligible expression in healthy volunteers; no influence of blood sample manipulation; stable expression for 36 hours on anticoagulated blood.

The other decisive advantage is the standardisation and automation of the measurement (performed in flow cytometry) thanks to a device developed by the LeukoDx company, the ACCELLIX-CD64. This measurement is performed in whole blood (30 to 50µL maximum), and the measurement time is short (26 minutes), which makes it particularly attractive in the context of emergency and resuscitation.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: December 31, 2018
• Est. primary completion date: December 9, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients admitted to the intensive care unit

Exclusion Criteria:

• Neutropenia (<500 neutrophils/mm3)

• Treatment by G-CSF or IFN-? during the week preceding admission to intensive care

• Age < 18 years

• Pregnancy

• Patient refusal

Related Conditions & MeSH terms

• Intensive Care
• Systemic Inflammatory Response Syndrome

Locations

Country	Name	City	State
France	CHRU de NANCY	Vandoeuvre les NANCY

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality at 28 days after admission		28 days